Publications by authors named "Basil Kopp"
Importance: Thromboprophylaxis is recommended for medical inpatients at risk of venous thromboembolism (VTE). Risk assessment models (RAMs) have been developed to stratify VTE risk, but a prospective head-to-head comparison of validated RAMs is lacking.
Objectives: To prospectively validate an easy-to-use RAM, the simplified Geneva score, and compare its prognostic performance with previously validated RAMs.
Overuse and underuse of thromboprophylaxis in medical inpatients.
Res Pract Thromb Haemost
August 2023
Article Synopsis
- The study investigates how different validated risk assessment models (RAMs) classify medical inpatients as high or low risk for venous thromboembolism (VTE) and how this impacts the appropriateness of thromboprophylaxis (TPX) prescriptions.
- Among 1352 patients analyzed, categorization as high risk varied significantly from 29.8% to 66.1% depending on the RAM used, with only about a quarter consistently classified by all models.
- The findings reveal underuse of TPX in high-risk patients and a concerning level of overuse in low-risk patients, pointing to inconsistencies in risk assessment and prescription practices.
Purpose: Prognosis for acute myeloid leukemia (AML) patients is poor, particularly in mutated AML, secondary, relapsed, and refractory AML, and in patients unfit for intensive treatment, thus highlighting an unmet need for novel therapeutic approaches. The combined use of compounds targeting the stem cell oncoprotein BMI1 and activating the tumor suppressor protein p53 may represent a promising novel treatment option for poor risk AML patients.
Experimental Design: The BMI1 inhibitor PTC596, MCL1 inhibitor S63845, and MEK inhibitor trametinib, as well as the p53 activator APR-246 were assessed as single agents and in combination for their ability to induce apoptosis and cell death in leukemic cells.